Tags

Type your tag names separated by a space and hit enter

CO2-laser for the genitourinary syndrome of menopause. How many laser sessions?
Maturitas. 2017 Oct; 104:24-28.M

Abstract

OBJECTIVES

The aim of this prospective study was to assess the efficacy of 3, 4 or 5 CO2-laser sessions for the management of the genitourinary syndrome of menopause (GSM).

METHODS

Postmenopausal women with moderate to severe symptoms of dyspareunia, wanting to resume/retain sexual activity, were treated with 3-5 laser sessions depending on symptom severity/presence, sexual function, clinical findings and women's preference following the third laser application.

MAIN OUTCOMES

Severity of dyspareunia, dryness, sexual function, sexual satisfaction and frequency of sexual intercourse defined the primary outcomes. Vaginal Maturation Value (VMV) and Vaginal Health Index Score (VHIS) defined the secondary ones.

RESULTS

Fifty-five women received three sessions, 53 an extra fourth and 22 an extra fifth. Following the third, fourth and fifth laser sessions, respectively: dyspareunia completely regressed in 15/55 (27%), 32/55 (58%) and 38/47 (81%) of participants; dryness completely regressed in 20/55 (36%), 36/55 (66%) and 44/51 (86%); normal sexual function resumed in 23/55 (41%), 37/54 (69%) and 41/49 (84%); VMV regained non-atrophic values in 29/55 (53%), 38/55 (69%) and 42/50 (84%); and VHIS regained non-atrophic values in 44/55 (80%), 53/55 (96%) and 55/55 (100%) of participants.

CONCLUSION

Results of this study indicate that CO2-laser therapy may contribute to complete regression of dyspareunia and dryness and reestablishment of normal sexual function in postmenopausal women, in a dose-response manner. An extra fourth or fifth session may further increase the GSM symptom-free rate.

Authors+Show Affiliations

Urogynaecology Unit, 1st Department of Obstetrics and Gynecology, "Alexandra" Hospital, National and Kapodistrian University of Athens, Greece. Electronic address: stavros.athanasiou@gmail.com.Urogynaecology Unit, 1st Department of Obstetrics and Gynecology, "Alexandra" Hospital, National and Kapodistrian University of Athens, Greece.Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece; Department of Medicine-Infectious Diseases, Iaso General Hospital, Athens, Greece; Department of Medicine, Tufts University School of Medicine, Boston, MA, USA.Urogynecology Unit, Obstetrics and Gynecology Unit, Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy.Urogynaecology Unit, 1st Department of Obstetrics and Gynecology, "Alexandra" Hospital, National and Kapodistrian University of Athens, Greece.

Pub Type(s)

Journal Article
Observational Study

Language

eng

PubMed ID

28923173

Citation

Athanasiou, Stavros, et al. "CO2-laser for the Genitourinary Syndrome of Menopause. How Many Laser Sessions?" Maturitas, vol. 104, 2017, pp. 24-28.
Athanasiou S, Pitsouni E, Falagas ME, et al. CO2-laser for the genitourinary syndrome of menopause. How many laser sessions? Maturitas. 2017;104:24-28.
Athanasiou, S., Pitsouni, E., Falagas, M. E., Salvatore, S., & Grigoriadis, T. (2017). CO2-laser for the genitourinary syndrome of menopause. How many laser sessions? Maturitas, 104, 24-28. https://doi.org/10.1016/j.maturitas.2017.07.007
Athanasiou S, et al. CO2-laser for the Genitourinary Syndrome of Menopause. How Many Laser Sessions. Maturitas. 2017;104:24-28. PubMed PMID: 28923173.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CO2-laser for the genitourinary syndrome of menopause. How many laser sessions? AU - Athanasiou,Stavros, AU - Pitsouni,Eleni, AU - Falagas,Matthew E, AU - Salvatore,Stefano, AU - Grigoriadis,Themos, Y1 - 2017/07/21/ PY - 2017/02/21/received PY - 2017/07/03/revised PY - 2017/07/19/accepted PY - 2017/9/20/entrez PY - 2017/9/20/pubmed PY - 2018/3/13/medline KW - Atrophy KW - Female Sexual Function Index (FSFI) KW - Genitourinary syndrome of menopause (GSM) KW - Menopause KW - Sexual dysfunction KW - Vulvovaginal atrophy (VVA) SP - 24 EP - 28 JF - Maturitas JO - Maturitas VL - 104 N2 - OBJECTIVES: The aim of this prospective study was to assess the efficacy of 3, 4 or 5 CO2-laser sessions for the management of the genitourinary syndrome of menopause (GSM). METHODS: Postmenopausal women with moderate to severe symptoms of dyspareunia, wanting to resume/retain sexual activity, were treated with 3-5 laser sessions depending on symptom severity/presence, sexual function, clinical findings and women's preference following the third laser application. MAIN OUTCOMES: Severity of dyspareunia, dryness, sexual function, sexual satisfaction and frequency of sexual intercourse defined the primary outcomes. Vaginal Maturation Value (VMV) and Vaginal Health Index Score (VHIS) defined the secondary ones. RESULTS: Fifty-five women received three sessions, 53 an extra fourth and 22 an extra fifth. Following the third, fourth and fifth laser sessions, respectively: dyspareunia completely regressed in 15/55 (27%), 32/55 (58%) and 38/47 (81%) of participants; dryness completely regressed in 20/55 (36%), 36/55 (66%) and 44/51 (86%); normal sexual function resumed in 23/55 (41%), 37/54 (69%) and 41/49 (84%); VMV regained non-atrophic values in 29/55 (53%), 38/55 (69%) and 42/50 (84%); and VHIS regained non-atrophic values in 44/55 (80%), 53/55 (96%) and 55/55 (100%) of participants. CONCLUSION: Results of this study indicate that CO2-laser therapy may contribute to complete regression of dyspareunia and dryness and reestablishment of normal sexual function in postmenopausal women, in a dose-response manner. An extra fourth or fifth session may further increase the GSM symptom-free rate. SN - 1873-4111 UR - https://www.unboundmedicine.com/medline/citation/28923173/CO2_laser_for_the_genitourinary_syndrome_of_menopause__How_many_laser_sessions DB - PRIME DP - Unbound Medicine ER -